News | VIVA | October 05, 2020

The Latest Vascular Interventional Clinical Data Presented at VIVA 2020

Top 10 trials listed below will be presented live

The Latest Vascular Interventional Clinical Data Presented at VIVA 2020 late-breaking sessions

October 5, 2020 — The Vascular Interventional Advances (VIVA) virtual conference will feature 10 late-breaking clinical trials sessions during the virtual meeting Nov. 6-7, 2020. A multidisciplinary, international panel of expert physicians, scientists and regulators will ask questions and shed light on the lasting impact of the research results as they are presented for the first time. 

For more information: https://vivaphysicians.org/clinical-trials

Friday, Nov. 6, 
Session beginning at 11 a.m. PT

   • 5-Year Outcomes from the IN.PACT Global Study. Presented by Thomas Zeller, M.D., Ph.D.

   • Drug-Coated Devices & Limb Outcomes After Endovascular Peripheral Artery Revascularizations. Presented by Connie N. Hess, M.D., MHS.

   • Standard vs Ultrasound-Assisted Thrombolysis for Submassive Pulmonary Embolism. Presented by Efthymios Avgerinos, M.D., Ph.D., MSc.

   • VIVO Study 12-Month Endpoint Results. Presented by Anthony Comerota, M.D.

   • PROMISE I 1-Year Results. Presented by Daniel Clair, M.D.

Saturday, Nov. 7 
Session beginning at 7 a.m. PT

   • DISRUPT PAD III RCT Acute Results: IVL vs PTA in Severe Calcium. Presented by William A. Gray, M.D.

   • REALITY Study: Directional Atherectomy Vessel Preparation Prior to DCB Angioplasty. Presented by Krishna Rocha-Singh, M.D.

   • 24-Month Outcomes from the DETOUR 1 Trial for Percutaneous Femoropopliteal Bypass. Presented by Ehrin Armstrong, M.D.

   • 2-Year Outcomes of a Multi-Centre Study on Infrapopliteal Bioresorbable Vascular Scaffold. Presented by Steven Kum, M.D.

   • 4-Year DCB Mortality Across ILLUMENATE RCTs. Presented by Sean Lyden, M.D.

 

Related VIVA Conference Content:

VIVA 2019 Late-breaking Clinical Trials

Other VIVA news


Related Content

News | Cardiovascular Clinical Studies

Nov. 10, 2025 —Genomics, a science-led techbio company, has today announced new research that suggests polygenic risk ...

Home November 12, 2025
Home
News | Cardiovascular Clinical Studies

Oct. 21, 2025 – AskBio Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG ...

Home October 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 25, 2025 — Merck, known as MSD outside of the United States and Canada, has announced that new clinical trial and ...

Home August 25, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 18, 2025 — (Newswise) It’s often mistaken for a heart attack, but Takotsubo cardiomyopathy — previously known as ...

Home August 21, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 20, 2025 — A major international study published in Atherosclerosis* has found that routinely testing for ...

Home August 20, 2025
Home
News | Cardiovascular Clinical Studies

Aug. 4, 2025 — Marea Therapeutics, Inc., a clinical-stage biotechnology company that develops next-generation medicines ...

Home August 04, 2025
Home
News | Cardiovascular Clinical Studies

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic ...

Home July 22, 2025
Home
News | Cardiovascular Clinical Studies

June 11, 2025 — Bayer and the Broad Institute have have extended their research collaboration of 10 years by an ...

Home June 11, 2025
Home
News | Cardiovascular Clinical Studies

May 27, 2025 — Despite scientific advances in cardiovascular care, people in living in rural areas and other communities ...

Home May 27, 2025
Home
News | Cardiovascular Clinical Studies

May 20, 2025 — Shockwave Medical, Inc., part of Johnson & Johnson MedTechhas announced the 30-day primary endpoint ...

Home May 21, 2025
Home
Subscribe Now